E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060612 |
E.1.2 | Term | Hemophilia A |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effects of secondary prophylaxis on bleeding frequency (number of all bleeds per year) compared to episodic treatment. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to evaluate the effect of secondary prophylaxis on the:
1. Change from baseline at Year 3 in the Extended MRI Scale total score. The Extended MRI Scale total score for each subject is defined as the average of the mean score for each type of joint (elbow, knee and ankle).
2. Change from baseline at Year 3 in the CAJAS Scale total score. The CAJAS Scale total score for each subject is defined as the average of the mean score for each type of joint (elbow, knee and ankle). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Males aged 18 to 50 years. Males aged 18 to 50 years in Bulgaria and Romania.
• Subjects with severe hemophilia A (<1% FVIII:C) as confirmed by the central lab from a sample obtained at least 96 hours after FVIII administration wash-out. Allow for the inclusion of a maximum of 10% (n=8) of patients with 1-2% FVIII:C baseline levels as long as they exhibit clinical severity and comply with all other inclusion criteria.
• Subjects with at least 150 prior exposure days with any FVIII.
Documentation can include records from previous physicians, specific home treatment records, emergency room or hospital records, etc. The investigator can also document it in a detailed note.
• Subjects who have been on episodic treatment and no known regular prophylaxis treatment for more than 12 consecutive months in the previous 5 years
• Subjects with 6 to 24 bleeding events bleeding events and/or treatments in the previous 6 months prior to study entry which are documented and available in the subject's medical records. Documentation can include records from previous physicians, specific home treatment records, emergency room or hospital records, x-ray reports, etc. The investigator can also document with a detailed note the number of bleeds reported by the subject in the last 6 months.
• Subjects with inhibitor formation surveillance (inhibitor or recovery testing) over the ten years prior to enrollment documented by the investigator and who do not have a history of any of the following:
o A positive inhibitor titer of 5.0 Bethesda Unit (BU) or greater by either BU assay system at any time since first exposure to exogenous factor VIII
o A positive inhibitor test result of 1.0 or greater performed by the original BU assay at any time in the past 10 years (A subject can have more than one positive inhibitor test of 0.6 or greater by the original BU assay test but all must be less than 1.0 BU using the original BU assay)
o A positive inhibitor test result of 0.6 or greater performed by the Nijmegen method at any time in the past 10 years
• Subjects with no inhibitor activity by Nijmegen-modified Bethesda assay, either positive (> 0.6 BU is considered positive) or borderline (> 0.3 and < 0.6 BU is considered borderline) as measured in the current
study reference laboratory.
• Subjects who complete the EPD device training and demonstrate the ability to correctly use it.
• Documented, signed, dated informed consent obtained prior to any study specific procedures being performed. |
|
E.4 | Principal exclusion criteria |
• Subjects with any other bleeding disease besides hemophilia A (ie, von Willebrand disease)
• Subjects with thrombocytopenia (platelets < 100,000/mm3)
• Subjects with abnormal renal function (Cockcroft-Gault Creatinine Clearance value of 60 mL/min or lower)
• Subjects with active hepatic disease (AST or ALT > 5xULN)
• Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study (the following drugs are however allowed: interferon-α treatment for HCV, HAART therapy for HIV and /or a total of two courses of pulse treatment with steroids for a maximumof 7 days at 1mg/kg or less)
• Subjects with an absolute CD4 lymphocyte cell count < 200 cells/mm3 (dueto HIV, HCV or another suspected medical condition)
• Subjects with known hypersensitivity to rFVIII, mouse or hamster proteins
• Subjects who are receiving or had received other experimental drugs within 1 month prior to study entry
• Subjects who require any pre-medication to tolerate FVIII injections (eg, anti-histamines)
• Subjects who are unwilling to comply with study visits or either of the possible treatment regimens
• Subjects who have a planned orthopedic intervention to be performed during the study that may substantially affect bleeding (eg, surgical or chemical or radiological synovectomy)
• Subjects who are not suitable for participation in this study for any reason, according to the Investigator
• Subjects who have poor joint status as defined by :
- Routine need for a wheelchair or unable to ambulate without the assistance of a brace, cane or crutches
- Three or more joints that are already fused or “frozen” (also called ankylosis) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Bleeding frequency and the specific endpoint is the total number of all bleeds. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary study efficacy parameter will be evaluated after all subjects who have not discontinued have completed one year. |
|
E.5.2 | Secondary end point(s) |
The secondary variables and their hierarchy are as follows:
1. Mean change from baseline to three years or LOCF (Last observation carried forward) in the MRI Scale. The MRI Scale score for each subject will be the mean change in the MRI scale score from baseline to 3 years for the mean of the joints with the lower scores at baseline for each type of joint: 1 elbow, 1 knee, and 1 ankle. (In the event of a tie, the joint with the worst change at three years or LOCF will be used.)
2. Mean change from baseline to three years or LOCF in the CAJAS. The CAJAS score for each subject will be the mean change in the CAJAS score from baseline to 3 years for the mean of the joints with the lower scores at baseline for each type of joint: 1 elbow, 1 knee, and 1 ankle. (In the event of a tie, the joint with the worst change at three years or LOCF will be used.)
3. Mean change from baseline to three years or LOCF in the Physical Functioning Domain of the Haemo-QoL–A |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
same compound but prophylaxis vs episodic treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Bulgaria |
Romania |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient Last Visit is a follow up phone call made to the study subject 1 month following the last study visit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |